Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017
July 26 2017 - 4:30PM
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, today announced that it will host a
conference call with members of Amarin senior management to discuss
the company's second quarter 2017 financial results and provide an
operational update on Wednesday, August 2, at 8:00 a.m. ET. The
conference call will follow the anticipated release of the
company's financial results earlier that day.
Event details:
The conference call can be heard live on the investor relations
section of the company's website at www.amarincorp.com, or via
telephone by dialing 877-407-8033 within the United States or
201-689-8033 from outside the United States. A replay of the call
will be made available for a period of two weeks following the
conference call. To hear a replay of the call, dial 877-481-4010,
(inside the United States) or 919-882-2331 (outside the United
States). A replay of the call will also be available through the
company's website shortly after the call. For both dial-in numbers
please use PIN: 16156.
To ask questions:
During the teleconference, following prepared remarks,
management will respond to questions from investors and analysts,
subject to time limitations. Participants in the live
teleconference will be provided an opportunity to ask questions.
Investors may also e-mail their questions to
investor.relations@amarincorp.com. E-mail questions will be
accepted until 4:00 p.m. ET on Tuesday, August 1, 2017.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty acids.
Amarin's clinical program includes a commitment to an ongoing
outcomes study. Vascepa® (icosapent ethyl), Amarin's first
FDA approved product, is a highly-pure, omega-3 fatty acid product
available by prescription. For more information about Vascepa
visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.
Availability of other information about
Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://investor.amarincorp.com), including but not limited to
investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that we post on these
channels and websites could be deemed to be material
information. As a result, we encourage investors, the media,
and others interested in Amarin to review the information that we
post on these channels, including our investor relations website,
on a regular basis. This list of channels may be updated from
time to time on our investor relations website and may include
social media channels. The contents of our website or these
channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Amarin contact information:
Investor Relations:
Elisabeth Schwartz
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Ovidio Torres
Finn Partners
In U.S.: +1 (312) 329 3911
Ovidio.torres@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024